Entering text into the input field will update the search result below

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q1 2021 Results - Earnings Call Transcript

May 07, 2021 12:50 AM ETLexicon Pharmaceuticals, Inc. (LXRX)
SA Transcripts profile picture
SA Transcripts

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2021 Earnings Conference Call May 6, 2021 6:00 AM ET

Company Participants

Chas Schultz - Executive Director of Corporate Communications & Patient Advocacy

Lonnel Coats - President and Chief Executive Officer and Director

Jeff Wade - Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer

Conference Call Participants

Jessica Fye - JPMorgan

Joseph Stringer - Needham & Company


Good morning, good afternoon and good evening. My name is Donna and I will be your conference operator today. At this time I would like to welcome everyone to Lexicon Pharmaceuticals Incorporated First Quarter's 2021 Earnings Call. [Operator Instructions]

I would now like to hand the conference over to your first speaker for today, Chas Schultz, Executive Director of Corporate Communications and Investor Relations. Thank you. Please go ahead, sir.

Chas Schultz

Thank you, Donna. Good afternoon and welcome to the Lexicon Pharmaceuticals first quarter 2021 financial results conference call. Joining me today are Lonnel Coats, Lexicon President and Chief Executive Officer and Jeff Wade, Lexicons Executive Vice President of Corporate and Administrative Affairs and Chief Financial Officer.

Earlier today lexicon issued a press release announcing our financial results for the first quarter of 2021, which is available on our website at lexpharma.com and through our SEC filings. A webcast for this call along with a slide presentation is available on our website. During this call, we will review the information provided in the release, provide an update on our clinical programs, and then use the remainder of our time to answer your questions.

Before we begin, let me remind you that we will be making forward looking statements including statements relating to the safety efficacy and the therapeutic and commercial potential of LX9211, sotagliflozin and other drug candidates. These statements may include characterizations of the expected

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.